ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Roivant Sciences Ltd (ROIV) is not a strong buy for a beginner, long-term investor at this time. While the stock has positive technical momentum and analyst optimism, the significant insider selling, poor financial performance, and lack of strong proprietary trading signals suggest caution. Holding the stock or waiting for better entry points is advised.
The stock shows bullish momentum with SMA_5 > SMA_20 > SMA_200 and a positive MACD histogram (0.186). RSI_6 at 75.25 is neutral but leaning toward overbought territory. Key resistance levels are R1: 28.798 and R2: 29.499, with the current pre-market price at 28.51 near R1.
Analysts have raised price targets significantly, with targets ranging from $26 to $38, citing strong Phase 2 data for brepocitinib in cutaneous sarcoidosis.
The company's pipeline has potential for rare disease treatments, which could drive long-term growth.
Insiders are selling heavily, with a 4331.98% increase in selling activity over the last month.
Financial performance is poor, with revenue down -77.83% YoY and net income down -256.98% YoY in Q3
No recent congress trading data or influential political activity to support the stock.
The company's Q3 2026 financials show significant declines: Revenue dropped to $1.99 million (-77.83% YoY), Net Income fell to -$265.89 million (-256.98% YoY), and EPS dropped to -0.38 (-265.22% YoY). Gross margin also decreased to 64.98%, down -33.10% YoY.
Analysts are overwhelmingly positive, with multiple firms raising price targets recently due to strong Phase 2 data for brepocitinib. Targets range from $26 (neutral) to $38 (buy), with several firms adding new revenue models for the drug.
